睿知中国医院研究地图
候选清单

南京

Nanjing Chest Hospital

在本站收录的 61 种疾病中,这家医院列在其中 1 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

Nanjing Chest Hospital的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肺癌Lung cancer25 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、胰腺癌、乳腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.1%。

牵头论文
25
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 3320222023: 3320232024: 3320242025: 442025

南京有 8 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
    分期
    I/II期
    开始
    2025-05
    发布
    登记号
    NCT06892548

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心临沂、北京、南京、南宁、南昌、厦门、合肥、宜昌、广州、徐州、成都、新乡、杭州、济南、福州、襄阳、西安、郑州、长春

  2. 正在招募
    A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
    分期
    未注明
    开始
    2025-12
    发布
    登记号
    NCT07143045

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心佛山、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、太原、广州、成都、扬州、昆明、武汉、沈阳、深圳、福州、郑州、重庆、长春、长沙、青岛

  3. 正在招募
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07182682

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

医院名称从作者地址自动识别,尚未人工核对。

牵头的论文25
  1. Three-Dimensional Computed Tomography Reconstruction in Uniportal Thoracoscopic Segmentectomy: A Propensity Score-matched Analysis.2026Surgical innovation
  2. Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50.2025Current cancer drug targets
  3. Clinical Efficacy and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Squamous Cell Lung Cancer: A Retrospective Single-Center Study in China.2025Current cancer drug targets
  4. The impact of EGFR-TKIs treatment on ground-glass opacity-featured lung adenocarcinama.2025Journal of cardiothoracic surgery免费全文
  5. UBE2Q1 as a novel cancer biomarker for lung adenocarcinoma.2025The American journal of the medical sciences
  6. Indocyanine green fluorescence identification of the intersegmental plane by the target segmental vein-first single-blocking during thoracoscopic segmentectomy.2024BMC surgery免费全文
  7. Silencing of ZNF610 suppresses cell proliferation and migration in lung adenocarcinoma.2024Cell biochemistry and function
  8. TFR1-Mediated Iron Metabolism Orchestrates Tumor Ferroptosis and Immunity in Non-Small Cell Lung Cancer.2024Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  9. Targeting TRIM9 by miR-218-5p Restricts Cell Proliferation and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.2023Annals of clinical and laboratory science
  10. Real-time image-guided indocyanine green fluorescence dual-visualization technique to measure the intraoperative resection margin during thoracoscopic segmentectomy.2023Asia-Pacific journal of clinical oncology
  11. The D ~ Sense ex-vivo viability assay application in a patient with stage IV lung adenocarcinoma: a case report.2023Journal of medical case reports免费全文
  12. Circular RNA-microRNA-mRNA network identified circ_0007618 and circ_0029426 as new valuable biomarkers for lung adenocarcinoma.2022Bioengineered免费全文
  13. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.2022Cancer chemotherapy and pharmacology免费全文
  14. Echinacoside Induces Mitochondria-Mediated Pyroptosis through Raf/MEK/ERK Signaling in Non-Small Cell Lung Cancer Cells.2022Journal of immunology research免费全文
  15. A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma.2021Bioengineered免费全文
  16. Diagnostic value of endobronchial ultrasound combined with rapid on-site evaluation of transbronchial lung biopsy for peripheral pulmonary lesions.2021Diagnostic cytopathologyRCT
  17. Serum tumour M2-pyruvate kinase as a biomarker for diagnosis and prognosis of early-stage non-small cell lung cancer.2021Journal of cellular and molecular medicine免费全文
  18. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer.2021Journal of cellular and molecular medicine免费全文
  19. Alginic acid inhibits non-small cell lung cancer-induced angiogenesis via activating miR-506 expression.2021Journal of natural medicines
  20. Concurrent vs sequential chemoradiotherapy for patients with advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.2021Medicine免费全文
  21. Challenges in Advanced Lung Cancer Diagnosis During the COVID-19 Pandemic.2021Technology in cancer research & treatment免费全文
  22. Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience.2021Technology in cancer research & treatment免费全文
  23. Improved diagnostic yield of transbronchial lung biopsy in peripheral pulmonary lesions using a combination of endobronchial ultrasound and rapid on-site evaluation.2021The Journal of international medical research免费全文
  24. Clinical significance of intrapulmonary lymph node dissection in pathological stage IA non-small cell lung cancer: A propensity score matching analysis.2021Thoracic cancer免费全文
  25. Feasibility investigation of near-infrared fluorescence imaging with intravenous indocyanine green method in uniport video-assisted thoracoscopic anatomical segmentectomy for identifying the intersegmental boundary line.2021Thoracic cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases正在招募NCT07143045研究中心2025-12 启动
  2. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery正在招募NCT07182682研究中心III期2025-12 启动
  3. A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer正在招募NCT06892548研究中心I/II期2025-05 启动
  4. Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT已完成NCT07309211研究中心2025-07 启动
  5. Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab进行中,不再招募NCT06211036研究中心III期2024-06 启动
  6. Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer状态不明NCT05513664研究中心2022-09 启动
  7. A Study of AL8326 in Non-Small Cell Lung Cancer进行中,不再招募NCT06794957研究中心I期2022-05 启动
  8. A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer进行中,不再招募NCT05047250研究中心III期2022-06 启动
  9. Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer已完成NCT04952597研究中心II期2021-07 启动
  10. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer已终止NCT04746924研究中心III期2021-05 启动
  11. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer已完成NCT04005716研究中心III期2019-07 启动
  12. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer状态不明NCT04641754研究中心II期2019-03 启动
  13. Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR状态不明NCT05767866研究中心I/II期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

Nanjing Chest Hospital

南京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR

提出更正下载数据